- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- Marc Faber: Chance of Global Recession Is Now 100%
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
- China, US, Japan Also Have Work to Do: EU's Barroso
MOST SHARED
- Carl Icahn Increases Stake in Chesapeake, Demands Board Seats
- Citigroup Lost $20 Million on Facebook IPO Trades
- Europe Has Wall Street's Bull on a Short Leash
- Romney Leads Poll Of Small Business Owners
- Marc Faber: 100% Chance of Global Recession
- Astronauts Snare SpaceX Rocket
- The Key to a Successful Turnaround
- Judge Says Skilling Can Seek New Trial
- Facebook: The Song — Yes, We're Serious
- Bacon Tourism: From the Davos of Bacon to Bacon Mecca
MOST POPULAR
HOT ON FACEBOOK
U.S. Seeks Stronger Warnings For Amylin's Byetta
Text Size 
U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.
 |
CNBC.com |
The Food and Drug Administration Monday said it had received six reports of hemorrhagic or necrotizing pancreatitis requiring hospitalization. Two of the patients died and the four others were recovering at the time of the reports.
The FDA said it was working with Amylin "to add stronger, more prominent warnings in the product label." Amylin co-markets the drug—one of the most successful new diabetes medicines in recent years—with Eli Lilly.
Amylin's shares [AMLN
Loading...
()
] were down about 15 percent at $28.95 in afternoon trading on the Nasdaq, while Eli Lilly's shares [LLY
Loading...
()
] fell 1.7 percent to $47.92 on the New York Stock Exchange.
Pancreatitis is an inflammation of the pancreas, which helps aid in digestion by releasing vital hormones. The condition usually subsides quickly, according to the Merck Manual of Medical Information.
Complications or death are rare, Amylin and Lilly said in a statement. Rates of such problems are about as common in patients taking the drug as in others who have pancreatitis.
In October, the FDA said it had reviewed 30 reports of pancreatitis in patients being treated with Byetta. At the time, Amylin agreed to add information about the risk on its drug label and to alert doctors about the problem.
It was not immediately clear if the FDA would order new so-called "black box'' warnings, the strongest type available, and representatives for the agency could not immediately be reached.
The companies said they would work with the agency to update the drug's label.
- The Nasdaq has suffered the most from the EU crisis showing there's risk in the usual tech stocks.
- Targeting more Millennials is just one of the items brewing for consumers in the world of spirits.
- It seems many people may need a reminder of how NOT to act on a plane. Here are a few tips.
- Here are some very unusual roadside stops along American highways that might peek your interest.
- How three generations of Americans are dealing with the finances of retirement.
Data is a real-time snapshot *Data is delayed at least 15 minutes
